关注
Piotr Ozieranski
Piotr Ozieranski
Reader in Sociology, Department of Social and Policy Sciences, University of Bath
在 bath.ac.uk 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Culture and behaviour in the English National Health Service: overview of lessons from a large multimethod study
M Dixon-Woods, R Baker, K Charles, J Dawson, G Jerzembek, G Martin, ...
BMJ quality & safety 23 (2), 106-115, 2014
5782014
How collaborative are quality improvement collaboratives: a qualitative study in stroke care
P Carter, P Ozieranski, S McNicol, M Power, M Dixon-Woods
Implementation Science 9, 1-11, 2014
632014
Exposing drug industry funding of UK patient organisations
P Ozieranski, E Rickard, S Mulinari
Bmj 365, 2019
582019
Walkrounds in practice: corrupting or enhancing a quality improvement intervention? A qualitative study
G Martin, P Ozieranski, J Willars, L McKee, K Charles, J Minion, ...
The Joint Commission Journal on Quality and Patient Safety 40 (7), 303-310, 2014
502014
Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland?
P Ozierański, M McKee, L King
Health Economics, Policy and Law 7 (2), 175-195, 2012
472012
Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK …
S Mulinari, P Ozieranski
BMJ open 8 (10), e023094, 2018
462018
The politics of health technology assessment in Poland
P Ozieranski, M McKee, L King
Health policy 108 (2-3), 178-193, 2012
402012
Analysis of pharmaceutical industry payments to UK health care organizations in 2015
P Ozieranski, M Csanadi, E Rickard, J Tchilingirian, S Mulinari
JAMA Network Open 2 (6), e196253-e196253, 2019
372019
A pill too hard to swallow: how the NHS is limiting access to high priced drugs
J Gornall, A Hoey, P Ozieranski
Bmj 354, 2016
372016
Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries
S Mulinari, L Martinon, PA Jachiet, P Ozieranski
Health Policy 125 (7), 915-922, 2021
342021
Failure of responsive regulation? Pharmaceutical marketing, corporate impression management and off-label promotion of enzalutamide in Europe
S Mulinari, C Davis, P Ozieranski
Journal of White Collar and Corporate Crime 2 (2), 69-80, 2021
312021
When health technology assessment is confidential and experts have no power: the case of Hungary
M Csanádi, O Löblová, P Ozierański, A Harsányi, Z Kaló, M McKee, ...
Health Economics, Policy and Law 14 (2), 162-181, 2019
312019
The emerging social science literature on health technology assessment: a narrative review
O Löblová, T Trayanov, M Csanádi, P Ozierański
Value in Health 23 (1), 3-9, 2020
262020
Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs
S Mulinari, A Vilhelmsson, E Rickard, P Ozieranski
PLoS One 15 (6), e0235021, 2020
242020
Evaluation of Financial and Nonfinancial Conflicts of Interest and Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal …
H Mamada, A Murayama, S Kamamoto, Y Kaneda, M Yoshida, S Sugiura, ...
Arthritis Care & Research 75 (6), 1278-1286, 2023
222023
Governing drug reimbursement policy in Poland: The role of the state, civil society, and the private sector
P Ozieranski, LP King
Theory and Society 46, 577-610, 2017
222017
Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review
P Ozieranski, L Martinon, PA Jachiet, S Mulinari
BMJ open 11 (12), e053138, 2021
212021
Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK
E Rickard, P Ozieranski, S Mulinari
Health Policy 123 (12), 1244-1250, 2019
212019
Multimethod study of a large-scale programme to improve patient safety using a harm-free care approach
M Power, L Brewster, G Parry, A Brotherton, J Minion, P Ozieranski, ...
BMJ open 6 (9), e011886, 2016
192016
The persistence of cliques in the post‐communist state. The case of deniability in drug reimbursement policy in Poland
P Ozierański, L King
The British journal of sociology 67 (2), 216-241, 2016
182016
系统目前无法执行此操作,请稍后再试。
文章 1–20